In Vitro Technologies

Permits and Restrictions	View Permits
Product Format	frozen Approx.10 µg
Storage Conditions	-20°C or colder in a manual defrost freezer. Avoid freeze-thawing.
Biosafety Level	1 Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Introduction	Cell Line Description: The HCC2218 cell line was initiated on April 10, 1996, and took 6 months to establish. HCC2218 was derived from a female whose family members included several members with cancer, four lung cancer patients (two of them, non-smokers), two breast cancer patients (one of them also had lung cancer) and one colon cancer patient. HCC2218 is a poorly differentiated cell line derived from the primary tumor of an invasive ductal carcinoma with metastases in 42/43 lymph nodes. The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53. HCC2218 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 [EGP2] and for cytokeratin 19. The cells are negative for expression of estrogen receptor (ER -), but positive for expression of progesterone receptor (PR +). DNA was isolated from an EBV-transformed lymphoblastoid cell line, HCC2218 BL, from the same patient is available as ATCC CRL-2363D.
Quality Control Specifications	DNA Quality Control Information: · > 100 kb in size by agarose gel electrophoresis · No RNA detected in the agarose gel · A260/A280 ratio ³ 1.8 · Tested and verified for PCR amplification and restriction digestion.

Introduction

Cell Line Description:

The HCC2218 cell line was initiated on April 10, 1996, and took 6 months to establish. HCC2218 was derived from a female whose family members included several members with cancer, four lung cancer patients (two of them, non-smokers), two breast cancer patients (one of them also had lung cancer) and one colon cancer patient. HCC2218 is a poorly differentiated cell line derived from the primary tumor of an invasive ductal carcinoma with metastases in 42/43 lymph nodes. The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53. HCC2218 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 [EGP2] and for cytokeratin 19. The cells are negative for expression of estrogen receptor (ER -), but positive for expression of progesterone receptor (PR +). DNA was isolated from an EBV-transformed lymphoblastoid cell line, HCC2218 BL, from the same patient is available as ATCC CRL-2363D.

Quality Control Specifications

DNA Quality Control Information:

· > 100 kb in size by agarose gel electrophoresis

· No RNA detected in the agarose gel

· A260/A280 ratio ³ 1.8

· Tested and verified for PCR amplification and restriction digestion.

Permits	These permits may be required for shipping this product to Australia: DAFF Import Permit formerly known as AQIS Import Permit must be obtained and a copy of the permit must be sent to ATCC in advance of shipment.
Basic Documentation	Product Sheet Certificate of Analysis SDS

Permits

These permits may be required for shipping this product to Australia:

DAFF Import Permit formerly known as AQIS Import Permit must be obtained and a copy of the permit must be sent to ATCC in advance of shipment.

Basic Documentation

Product Sheet Certificate of Analysis SDS

E: care@invitro.com.au
P: 1300 552 003

Request a quote or demo
Contact a Specialist

HCC2218; Breast Carcinoma; Genomic DNA, Human Item ID: ATCCRL2343D

Contact Us